Abstract Survival of patients with chronic myeloid leukemia (CML) has improved with the use of imatinib and other tyrosine kinase inhibitors. There is limited data on second primary malignancies (SPM) in CML. We analyzed the SPMs rates among CML patients reported to Surveillance, Epidemiology, and End Results (SEER) database during pre- (1992)(1993)(1994)(1995)(1996)(1997)(1998)(1999)(2000) and post-(2002-2009) era. We used SEER Multiple Primary-Standardized Incidence Ratio session to calculate standardized incidence ratios (SIRs). Among 8,511 adult CML patients, 446 patients developed 473 SPMs. The SIR for SPMs in CML patients was significantly higher with observed/expected ratio:1.27, P \ 0.05 and absolute excess risk of 32.09 per 10,000 person years compared to general population. The rate of SPMs for cancers of all sites in post-imatinib era were significantly higher compared to pre-imatinib era with observed/expected ratio of 1.48 versus 1.06, P = 0.03. This study showed that risk of SPMs is higher among CML patients. The risk of SPMs is significantly higher in postimatinib era compared to pre-imatinib era.
Introduction
Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder accounting for 15 % of adult leukemias. It is characterized by translocation t(9;22) resulting in the fusion gene (bcr-abl) product which is central to the development of the malignancy. Imatinib, which selectively inhibits bcrabl tyrosine kinase in CML patients, was approved by Food and Drug Administration in May 2001 based on the findings of International Randomized Study of Interferon and ST1571 trial [1] . In this pivotal trial, 1,106 newly diagnosed CML patients were randomized to receive either imatinib 400 mg a day or interferon alpha plus low dose cytarabine. Results of this trial showed that imatinib induced major/ complete cytogenetic responses in[85 % of the patients and was associated with a relapse-free survival and overall survival of approximately 80 and 95 %, respectively. Because of high risk of relapse after stopping imatinib, or second generation TKIs such as nilotinib or desatinib, current recommendation is to continue the treatment with these drugs indefinitely outside the context of clinical trials. A potential immunosuppressive effect of imatinib was previously reported [2] . If this finding may lead to an increased risk of cancer in humans is still unknown [3] . In addition, a preclinical study showed the carcinogenic potential of imatinib [4] . We conducted a population based study utilizing The Surveillance, Epidemiology, and End Results (SEER) database to evaluate the incidence of SPM in CML patients in pre-and post-imatinib eras. The rate of SPMs for cancers of all sites in post-imatinib era was significantly higher compared to pre-imatinib era with observed/expected (O/E) ratio of 1.06 versus 1.48, P = 0.0007. The AERs for cancers of all sites in pre-imatinib and post-imatinib era were 7.69 and 58.21 respectively. Similarly, the rates of SPMs for cancers of all sites excluding non-melanoma skin cancer were significantly 
Methodology

Anylasis by Age Groups
We analysed SPM rates by age groups 20-49, 50-69, and 70? years during both pre-and post-imatinib era. For patients aged 50-69 years, all sites SPM was significantly increased in post-imatinib era as compared to pre-imatinib era with O/E ratio 0.93(n = 39) versus 1.62 (n = 63), P = 0.0027, and all solid tumor O/E ratio 0.81(n = 31) versus 1.53 (n = 4), P = 0.002. All site SPM was also increased in 70? years age group patients in post-imatinib era with O/E ratio 0.94(n = 73) versus 1.32 (n = 96), P = 0.01 (Table 2 ). There was also increase in O/E ratio and excess risk of liver and biliary, melanoma, endocrine SPM in 50-69 years age group in post-imatinib era but the increase was not statistically significant as compared to pre-imatinib era. Similarly, digestive system tumor O/E ratio and excess risk increased in 70? age groups in post-imatinib era but it was not statistically as compared to pre-imatinib era. All site tumor was increased in post-imatinib era 50-69 years age group, P = 0.0027, and 70? years age group, P = 0.01. All solid tumor was significantly increased in 50-69 years age group, P = 0.002.
Latency to the Development of Second Primary Malignancy
Patients were followed for median time of 19 months (range 1-85 months) and 13 months (range 1-91 months) in pre-and post-imatinib era respectively. The risk of second primary cancer was highest within 1-11 months for all age groups in post-imatinib era (Table 3) .
Discussion
Improvement in survival of CML is a success story and is largely due to approval of tyrosine kinase inhibitors. Our previous population based study [6] showed that the survival benefit has translated to population based settings. This is the largest study to evaluate second primary cancers in patients with CML. This study showed that overall risk of second malignancies among CML patients is higher compared to general population. There is significantly higher risk for SPM of digestive system, liver and biliary, adrenal, lymphatic and hematological malignancy. A recent study from Europe [7] showed slight increase in secondary malignancies in CML patients compared to general population. In this study, the age standardized incidence rates of secondary malignancies in CML patients were 535 and 582 per 100,000 for men and women respectively. The incidence rates for general population in Germany were 450 and 350 per 100,000 for men and women. These findings are important in view of improved survival among CML patients. These patients may benefit from regular examination for other malignancies during their follow up visits.
Interestingly, the overall risk of second primary malignancies is significantly higher in post-imatinib era. However, there was no significant difference in risk of specific SPMs. This may be because of rarity of this late complication. In a 2 year rat carcinogenicity study [8] that included administration of imatinib at 15, 30 and 60 mg/kg/day showed neoplastic changes in renal tubule, renal pelvis, urinary bladder, urethra, preputial and clitoral glands, small intestine, parathyroid glands, adrenal glands, and non glandular stomach. Neoplastic changes were not observed at 30 mg/kg/day for the kidneys, urinary bladder, urethra, small intestine, parathyroid glands, adrenal glands and non-glandular stomach, and at 15 mg/kg/day for preputial and clitoral gland. A previous study [9] did not show any significant increase in risk of secondary cancers from exposure to tyrosine kinase inhibitors. In this study, records of 1,445 patients with CML/ Myeloproliferative neoplasm and other hematologic malignancies treated with TKIs were reviewed. The risk of second cancer was found to be lower than expected risk with observed to expected ratio 0.6, 95 % confidence interval 0.44-0.81. This study however, did not include CML patients only. In contrast, our study included larger number of patients with CML only. Second primary malignancy is a rare event and relatively smaller sample size in the study by Verma D et al. [9] may be responsible for lack of association between imatinib and SPMs.
The increase in SPMs in CML patient in post-imatinib era is unexplained. The use of tyrosine kinase for treatment of CML may be responsible for significant increase in second primary malignancies.
Another potential explanation of increased SPMs rate in post-imatinib era may be inherent higher risk of SPMs among CML patients. Since survival of CML patients has improved with use of TKI, more SPMs are being diagnosed in these patients.
It may be important to screen patients with CML for second primary malignancies during follow up visits. This is specifically more important in older patients and during the first year of diagnosis of CML.
Conclusion
Risk of second primary malignancies is significantly higher in patients with CML. SPM rate has significantly increased during post-imatinib era compared to pre-imatinib era.
